Abstract
The complement system comprises a set of essential molecules that bridge the innate and adaptive immune responses. Research has focused on how the complement system's destructive mechanism could potentially be harnessed for cancer treatment. However, cancer subverts the complement system to avoid immunosurveillance. In addition, a complement-triggered biological mechanism that contributes to cancer growth has been identified. Thus, drugs should be designed to homeostatically maintain a normal concentration of complement. This review explores three types of complement-related anti-cancer drugs: therapeutic antibodies, complement inhibitory drugs, and anti-complement regulatory drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 420-431 |
| Number of pages | 12 |
| Journal | Microbiology and Biotechnology Letters |
| Volume | 44 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Dec 2016 |
Keywords
- Complement
- Immune system
- Immunosurveillance
- Inflammation
- Therapeutics
- Tumour cells
